1800-272-662
Shopping Cart 0
countryflagAU
Login

Zelira Therapeutics Ltd

Healthcare AU ZLD

0.5AUD
-(-%)

Last update at 2026-03-11T23:00:00Z

Day Range

0.500.50
LowHigh

52 Week Range

0.311.15
LowHigh

Fundamentals

  • Previous Close 0.50
  • Market Cap5.95M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.17411M
  • Revenue TTM0.00066M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.80295M
  • Diluted EPS TTM-0.32

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -3.84967M -36.73976M -6.26873M -12.41352M -8.54908M
Minority interest 0.22M 0.17M 0.70M 0.47M -
Net income -3.62787M -36.56890M -5.57301M -11.94530M -8.54908M
Selling general administrative 1.65M 1.34M 3.06M 6.08M 4.49M
Selling and marketing expenses 0.01M 0.03M 0.07M 0.72M 0.51M
Gross profit -0.80295M 0.01M -0.06144M 0.60M 0.44M
Reconciled depreciation 0.27M 0.48M 0.55M 0.59M 0.47M
Ebit -4.32116M -36.92022M -5.92556M -12.35967M -8.50645M
Ebitda -4.17411M -36.44118M -5.38033M -11.77113M -8.03220M
Depreciation and amortization 0.15M 0.48M 0.55M 0.59M 0.47M
Non operating income net other - - - - -
Operating income -3.95219M -5.93823M -7.16418M -13.20630M -9.37993M
Other operating expenses 3.95M 6.27M 6.49M 13.91M 9.17M
Interest expense 0.41M 0.74M 0.08M 0.05M 0.04M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - 0.00031M 0.08M 0.01M 0.00072M
Net interest income -0.40721M -0.73896M -0.07653M -0.04325M -0.04190M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.15278M -0.91973M 0.72M 0.86M 1.30M
Total revenue 0.00066M 0.09M 0.30M 1.54M 0.66M
Total operating expenses 3.15M 5.95M 7.20M 14.25M 10.20M
Cost of revenue 0.80M 0.08M 0.36M 0.94M 0.23M
Total other income expense net 0.10M -30.80153M 1.07M 1.28M 1.25M
Discontinued operations - - - - -
Net income from continuing ops -3.84967M -36.73976M -6.26873M -12.41352M -8.54908M
Net income applicable to common shares -3.62787M -36.56890M -5.57301M -11.94530M -8.54908M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 1.30M 5.18M 33.89M 37.70M 39.37M
Intangible assets 0.52M - 0.81M 0.97M 1.12M
Earning assets - - - - -
Other current assets - 0.11M 0.11M 0.27M 0.21M
Total liab 5.59M 9.36M 2.18M 2.01M 1.54M
Total stockholder equity -4.46043M -4.51492M 31.80M 35.20M 37.83M
Deferred long term liab - - - - -
Other current liab - - 0.14M 0.12M 0.09M
Common stock - 45.52M 45.52M 43.75M 36.65M
Capital stock 45.52M - 45.52M 43.75M 36.65M
Retained earnings -84.96404M -81.33617M -44.76727M -39.19426M -27.24895M
Other liab - - - - -
Good will - - 30.75M 30.75M 30.75M
Other assets - - 0.04M 0.06M 0.10M
Cash 0.00566M 0.59M 0.15M 2.75M 4.97M
Cash and equivalents - - - - -
Total current liabilities 5.59M 7.09M 1.88M 1.63M 1.08M
Current deferred revenue - - -0.14253M -0.11671M -0.09053M
Net debt 1.98M 3.25M 0.29M -2.24550M -4.42004M
Short term debt - 3.69M 0.14M 0.12M 0.09M
Short long term debt 1.99M - - - -
Short long term debt total - 3.84M 0.44M 0.50M 0.55M
Other stockholder equity - - -0.57018M 30.65M 28.43M
Property plant equipment - - 0.52M 0.85M 1.24M
Total current assets 0.61M 4.26M 1.77M 5.08M 6.09M
Long term investments 0.04M - 0.04M 0.06M 0.17M
Net tangible assets - - 0.24M 3.49M 5.96M
Short term investments - - - - -0.09985M
Net receivables 0.00469M 2.31M -0.00109M 0.26M 0.06M
Long term debt - - - - -
Inventory 0.48M 1.25M 1.53M 1.96M 0.87M
Accounts payable 3.45M 3.41M 1.74M 1.51M 0.98M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 31.31M 31.05M 30.65M 28.43M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.65M -32.07635M -32.56124M -33.17553M
Deferred long term asset charges - - - - -
Non current assets total 0.69M 0.92M 32.12M 32.63M 33.28M
Capital lease obligations 0.15M - 0.44M 0.50M 0.55M
Long term debt total - - 0.30M 0.38M 0.46M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 1.15M 0.92M 2.83M -0.20778M 1.38M
Change to liabilities - - 0.23M 0.53M 0.43M
Total cashflows from investing activities 1.15M 0.92M 2.83M -0.20778M 1.38M
Net borrowings 3.19M 3.92M - - -
Total cash from financing activities 3.19M 3.92M 1.77M 7.10M 10.53M
Change to operating activities - - - - -
Net income -3.62787M -36.56890M -5.57301M -11.94530M -8.54908M
Change in cash -0.58050M 0.60M -2.60020M -2.22471M 3.27M
Begin period cash flow 0.59M -0.01522M 2.75M 4.97M 1.70M
End period cash flow 0.00566M 0.59M 0.15M 2.75M 4.97M
Total cash from operating activities -4.90685M -4.38859M -7.24908M -9.42722M -8.61658M
Issuance of capital stock - - 1.77M 7.10M 10.62M
Depreciation 0.27M 0.48M 0.55M 0.59M 0.47M
Other cashflows from investing activities 1.15M 0.92M 2.83M -0.20778M 1.38M
Dividends paid - - - - -
Change to inventory 0.77M 0.28M 0.36M -1.08956M -0.86759M
Change to account receivables 0.18M -0.21149M 0.28M -0.12098M -0.11590M
Sale purchase of stock -0.00240M - 1.77M 7.10M -0.08800M
Other cashflows from financing activities 1.09M 0.92M 2.83M -0.20778M 1.38M
Change to netincome - - -3.08462M 2.62M 0.02M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.95M 1.73M 0.63M -1.21054M -0.98349M
Stock based compensation -1.18741M 0.04M 0.40M 2.69M 1.30M
Other non cash items -1.31389M 30.41M -2.22130M 1.93M -0.54176M
Free cash flow -4.90685M -4.38859M -7.24908M -9.42722M -8.61658M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ZLD
Zelira Therapeutics Ltd		 - -% 0.50 - 5.78 9067.95 0.33 10147.40 -1.0946
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.

Zelira Therapeutics Ltd

101 St Georges Terrace, Perth, WA, Australia, 6000

Key Executives

Name Title Year Born
Mr. Osagie O. Imasogie Esq. Founder & Chairman 1962
Dr. Oludare Odumosu MD, Global CEO & Director NA
Mr. Timothy Ryan Slate Non-Exec. Director & Company Sec. NA
Mr. Rahul Ganesan VP of Fin. & Accounting NA
Mr. Greg Blake VP of Global and Head of Commercial & Partnering NA
Dr. Patty Washer Clinical Trial Consultant NA
Mr. Greg Blake Executive Director NA
Mr. Timothy Ryan Slate Company Secretary & Non-Executive Director NA
Mr. Rahul Ganesan Vice President of Finance & Accounting NA
Mr. Greg Blake Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.